Non-pathogenic Anti-Desmoglein 3 IgG Autoantibodies in Fogo Selvagem  by Amagai, Masayuki
COMMENTARY
© 2006 The Society for Investigative Dermatology www.jidonline.org 1931
Non-pathogenic Anti-Desmoglein 3 
IgG Autoantibodies in Fogo Selvagem
Masayuki Amagai1
The endemic form of pemphigus foliaceus, fogo selvagem, is caused by IgG 
autoantibodies directed against desmoglein 1 (Dsg1). Hilario-Vargas and his 
colleagues describe a high prevalence of IgG autoantibodies against Dsg3, the 
target antigen of pemphigus vulgaris, in a Brazilian population where fogo sel-
vagem is endemic, although those patients do not develop any apparent clinical 
phenotype of pemphigus vulgaris.
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Pemphigus is an autoimmune blistering 
disease of the skin and mucous mem-
branes and has two major classic forms, 
pemphigus vulgaris (PV) and pem-
phigus foliaceus (PF). PF has a unique 
endemic subtype, fogo selvagem, that 
is found in certain regions of Brazil and 
is thought to be caused by an environ-
mental factor(s). Patients with fogo sel-
vagem show clinical and histological 
findings similar to those of patients with 
sporadic PF and have been considered 
to have similar serological findings for 
a long time. Hilario-Vargas and his col-
leagues (2006, this issue) describe that 
a subset of patients with fogo selvagem 
have anti-desmoglein 3 (anti-Dsg3) IgG 
autoantibodies.
Patients with pemphigus devel-
op IgG autoantibodies against des-
mogleins, cadherin-type cell–cell 
adhesion molecules found in desmo-
somes. Desmoglein has four isoforms: 
Dsg1, Dsg2, Dsg3, and Dsg4. Dsg2 is 
expressed in all desmosome-bearing 
tissues, including simple epithelia and 
myocardium, whereas expression of 
Dsg1 and Dsg3 is basically restricted 
to stratified squamous epithelia. Dsg4 
is the most recently discovered iso-
form, also expressed in stratified squa-
mous epithelia, but in more specified 
regions, such as in the granular and 
cornified cell layers of the epidermis 
and in the matrix cells of the anagen 
hair bulb (Bazzi et al., 2006). In gener-
al, patients with PF have anti-Dsg1 IgG 
autoantibodies, but not anti-Dsg3 IgG 
autoantibodies. Patients with mucosal 
dominant-type PV have anti-Dsg3 IgG, 
but not anti-Dsg1 IgG. Patients with 
mucocutaneous-type PV have both 
anti-Dsg3 and anti-Dsg1 IgG. Several 
patients with PF or mucocutane-
ous-type PV have IgG autoantibodies 
against Dsg4, although this Dsg4 reac-
tivity is due to the crossreactivity of a 
subset of anti-Dsg1 IgG autoantibodies 
(Nagasaka et al., 2004).
The above correlation between the 
anti-Dsg antibody profile and the clini-
cal phenotype is well built. This is fur-
ther supported by the fact that changes 
in clinical phenotype occur along with 
changes in anti-Dsg antibody profiles; 
for example, when patients showed 
clinical transition from PF to PV, anti-
Dsg1 IgG was detected in the PF stage 
and anti-Dsg3 IgG was developed in 
the PV stage (Komai et al., 2001). In 
addition, the correlation is logically 
explained by desmoglein compensation 
theory (Mahoney et al., 1999).
However, this correlation does not 
hold true when the autoantibodies 
are detected but are non-pathogen-
ic or not potent enough to cause the 
disease, as is often seen in patients 
in clinical remission. In patients in 
re mission, although anti-Dsg1 or -Dsg3 
autoantibodies are detected in sera by 
ELISA or immunofluorescence, there is 
no clinical phenotype for pemphigus. 
The non-pathogenic state is explained 
by decreased titers of the autoantibod-
ies (Cheng et al., 2002) or epitope shift 
against different domains of desmo-
glein molecules (Li et al., 2003).
Recently, Warren and his colleagues 
in Luis A. Diaz’s laboratory identified a 
new focus of fogo selvagem in Limão 
Verde, Brazil, where the prevalence of 
the disease is 3.4% (a total of 31 patients 
in a population of 916) and found that 
30 of 31 patients had circulating anti-
Dsg1 IgG autoantibodies (Warren et 
al., 2000). Interestingly, the detectable 
anti-Dsg1 IgG was also found in 55% of 
normal subjects living in this endemic 
focus, and at lower levels in normal sub-
jects living in nearby areas. Furthermore, 
anti-Dsg1 IgG was also detected in 
patients with fogo selvagem up to 4 years 
before the onset of clinical disease, with 
a marked increase in antibody titers 
against Dsg1 in association with onset 
of clinical disease. Subsequently, the 
researchers found anti-Dsg3 IgG in 7% 
(19 of 276) of patients with PF or fogo 
selvagem by ELISA as well as immuno-
precipitation and further demonstrated 
that purified anti-Dsg3 IgG from PF or 
fogo selvagem patients is capable of 
inducing blisters with typical histology 
of PV in neonatal mice when passively 
transferred (Arteaga et al., 2002).
Hilario-Vargas and his colleagues 
(2006, this issue), as an extension of 
their consistent investigation on fogo 
selvagem, describe that anti-Dsg3 IgG 
was detected by ELISA in 43% (9 of 
21) of patients with fogo selvagem and 
also in 20% (61 of 304) of normal sub-
jects living in the endemic Limão Verde. 
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 The proportion of 
normal subjects with 
anti-Dsg3 IgG increased 
with increasing 
proximity of their place 
of residence to the 
endemic area.
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Furthermore, the proportion of normal 
subjects with anti-Dsg3 IgG increased 
with increasing proximity of their place 
of residence to the endemic area. No 
apparent crossreactivity between anti-
Dsg1 and anti-Dsg3 IgG was found in 
the fogo selvagem patients. Although 
the authors detected anti-Dsg3 IgG in 
those patients with fogo selvagem, none 
of them developed any obvious clinical 
phenotype of PV, such as oral lesions. It 
is not clear why those patients with anti-
Dsg3 IgG in addition to anti-Dsg1 IgG 
do not show the clinical phenotype of 
mucocutaneous-type PV. A part of the 
reason could be that the quantities of 
pathogenic anti-Dsg3 IgG were insuffi-
cient to induce the PV phenotype, as the 
authors found that the intensity of immu-
noprecipitated Dsg3 was less strong than 
that of Dsg1.
Certainly, fogo selvagem provides a 
fascinating model in autoimmune dis-
eases. Now we know that an uniden-
tified environmental factor(s) triggers 
not only anti-Dsg1 IgG but also anti-
Dsg3 IgG autoantibodies. This finding 
offers new insight into the epidemio-
logy of fogo selvagem and provides 
a framework for better understanding 
of immunological mechanisms of the 
onset of autoimmune response against 
desmogleins in pemphigus.
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Pathways to the Development of 
Melanoma: A Complex Issue
Marianne Berwick1
The investigation of nevus distribution by anatomic site has led to interesting 
hypotheses of divergent pathways to the development of melanoma. However, 
such hypotheses must be viewed in all their complexity, and the paper by Randi 
et al. gives additional substance to this complexity.
Journal of Investigative Dermatology (2006) 126, 1932–1933. doi:10.1038/sj.jid.5700419
In this issue, Randi et al. (2006) report 
on a carefully conducted case-con-
trol study of melanoma conducted 
by a collaborative group, the Italian 
Group for Epidemiologic Research in 
Dermatology (GISED), from 1992 to 
1994. Dermatologists counted nevi on 
both cases and controls. The authors 
state that there was an effect of nevi at 
all sites, but no site-specific associa-
tion, except for the posterior trunk. They 
suggest that their interpretation of the 
data runs counter to the very interest-
ing hypothesis raised in 2003 by David 
Whiteman and his colleagues, who 
suggested different etiologic pathways 
for melanomas on the head and neck 
and melanomas on the trunk. Further 
genetic support for such a hypothesis 
has been found in the data presented by 
Curtin and his colleagues (Curtin et al., 
2005; Maldonado et al., 2003; Bastian 
et al., 2003) when they investigated 
somatic mutations in BRAF. However, it 
may be best to modify this hypothesis 
to state that different etiologic pathways 
may consist of (1) aberrant melanogen-
esis and (2) cumulative sun exposure 
among susceptible individuals. The 
difference here is that the pathways as 
suggested are similar, but the focus is 
on biology rather than anatomic site.
In evaluating the difference between 
the two alternative (although comple-
mentary) hypotheses, it is helpful to 
look at a table of subjects in three epi-
demiologic studies (Randi et al., 2006; 
Whiteman et al., 2003; Berwick et al., 
unpublished data) arranged by ana-
tomical site and to review several dif-
ferences among the studies (Table 1).
It is immediately obvious that there 
are important differences in the site dis-
tribution of nevi. These differences can in 
part, but not wholly, be explained by the 
oversampling used by Whiteman et al. 
(2003), because Randi et al. (2006) had 
a very much larger proportion of indi-
viduals with melanoma of the head and 
neck. In fact, a Spanish study by Ocaña-
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